# Myelin VC

Myelin VC is a Private Equity based in Madrid, Spain.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Madrid, Spain
- **Region:** Europe
- **Address:** Madrid, Spain
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** www.myelin.vc
- **LinkedIn:** https://www.linkedin.com/company/myelin-vc

## Regulatory record

- **Reports private funds:** No

## About

Myelin VC is a venture capital firm founded in 2019 in Madrid, Spain. It invests in founders across various industries, providing funding from seed to series A stages. The firm has made 60 investments, including a Series A investment in Midas on March 30, 2026.

## Sectors

- Digital Health
- FinTech
- Enterprise Software
- SpaceTech
- ClimateTech
- AI/ML
- FoodTech
- PropTech
- Mobility & Transportation
- FemTech
- Pet Care
- EdTech

## People

- Matías Nisenson — Team
- Martin Varsavsky — Team
- Alec Oxenford — Team
- Federico Jack — Team
- Gaston Maffei — Team
- Catalina Plorutti — Team
- Milos Fulton — Team
- Cesar Levene — Team

## Questions

### Who runs investment decisions at Myelin VC?

The investment team is composed of eight principals, all with prior founder experience. Matías Nisenson and Martin Varsavsky are the most visible partners, with Alec Oxenford, Federico Jack, Gaston Maffei, Catalina Plorutti, Milos Fulton, and Cesar Levene rounding out the group. The firm does not publicly designate a CIO or specify how investment committee votes are structured.

### Does Myelin VC operate as a traditional venture fund or a founder syndicate?

Myelin VC is structured as a private equity firm rather than an ad hoc syndicate, but it does not publicly disclose its fund vehicles, LP composition, or fund sizes. The partner-heavy, institutional-light model — combined with an industry-agnostic mandate — gives the firm a posture closer to a permanent-capital operator collective than a typical European VC fund.

### Does Myelin VC participate in follow-on rounds after the initial check?

The firm states it invests 'from seed through series A,' implying at least one follow-on capability. However, Myelin does not publicly disclose reserve ratios or describe its follow-on strategy, leaving open the question of whether it leads later rounds or maintains pro-rata on a case-by-case basis.

## Related profiles

- [MY EG Capital](https://altss.com/profile/my-eg-capital)
- [Myeloma Investment Fund](https://altss.com/profile/myeloma-investment-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/myelin-vc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology